Company

About us

Scintomics Molecular, Applied Theranostics Technologies (SCI-att) is a growing player in the radiopharmaceutical business with a particular strategic emphasis on providing unrestricted supply and support of proprietary and innovative tracer technology and non-IP protected precursors.

The well-known GRP Module Series became part of SCI-att in April 2020 when SCI-att took over the Module business from its parent company Scintomics, which has been selling and installing fully automated production systems for established radio-pharmaceuticals in clinical facilities around the world since 2006.

0
+
Happy Clients
0
Years In Business
0
Countries
0
Cups of Coffee

2Quart Medical 2Quart Medical
Mezenhof 83
1742 Schagen
NOORD-HOLLAND / Netherlands
CardiRad CardiRad Sweden AB
Karusellplan 8
12631 Hägersten
Sweden

DSD Pharma DSD Pharma GmbH
Schuhmeierstraße 24
1140 Purkersdorf
Austria
Global Medical Solutions Global Medical Solutions Pty Ltd
253 Princes Hwy
2205 Arncliffe, NSW
Australia
Health Technologies Health Technologies Sp. Z.o.o.
Chocimska 20/101
00-791 Warszawa
Poland
Imaxeon Imaxeon Pty. Ltd.
Unit 1, 38-46 South Street
Rydalmere NSW 2116
Australia
MediRay Mediray GPC
Aetideon 2 & Mesogeion 224
15561 Holargos
Athen
Greece
Nepha Nepha Tibbi Cihazlar SAN.VE TIC. A.S
Sedat Simavi Sok, Gul Apt 21A
06550 Çankaya/Ankara,
Turkey
Imaxeon QT Instruments (S) Pte. Ltd.
192 Pandan Loop SGP
#06-20 Pantech Business Hub
128381 Singapore
Tecnasa TECNASA, Tecnologias Asociadas
c/ Primera, 27
28016 Madrid
Spain
Vega Medical VEGA Medical
Boul. Bulgaria 109, fl.2, office 2.6 Vertigo Tower
1404 Sofia
Bulgaria

Our Scintomics/att History

Scintomics

Scintomics, a privately held company based near Munich/Germany, is committed to targeted theranostics and corresponding radiopharmaceutical technologies. Its strong focus towards personalized cancer care is reflected by an exceptional and continuously growing portfolio of innovative tracer technologies and the clinical development of Theranostic through subsidiaries, joint ventures and alliances.

 

Its subsidiary Scintomics Molecular, Applied Theranostics technologies continues Scintomics ́ radiopharmaceutical business segment in an independent manner with a particular strategic emphasis on providing unrestricted supply and support of Scintomics proprietary and innovative tracer technology and non-IP protected precursors as well as the more than 15 year experience in Synthesis Modules.